OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce that it will be presenting at Biotech Showcase in San Francisco, January 8-10 2024. The OKYO management team will also be participating in one-on-one partnering meetings throughout the conference.
Related news for (OKYO)
- OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
- 24/7 Market News Snapshot 16 July, 2025 – OKYO Pharma Limited Ordinary Shares (NASDAQ:OKYO)
- Don’t Miss Out: MoBot’s Latest Stock Updates 03/12/25 06:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 03/12/25 05:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 01/29/25 09:00 AM